
News|Articles|June 21, 2004
Now there's safe, effective relief for innocents abroad
Clinicians can now offer their patients the first nonsystemic, gastrointestinal selective antibiotic to receive FDA approval. The agency recently approved rifaximin (Xifaxan, Salix Pharmaceuticals) tablets for the treatment of TD caused by noninvasive strains of Escherichia coli in those 12 years of age or older. Rifaximin is currently approved for use in 17 countries worldwide. It is expected to be available in U.S. pharmacies in August.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
2
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
3
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
4
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
5




























